HomeHealth CareBiotechnology

Biotechnology

TriMed Reaches End Stage In Deal with Henry Schein

Howard Fine - April 23, 2024

Biotechnology

Brent Reinke and the 101 Biotech Corridor

Howard Fine - March 29, 2024

Biotechnology

Skin in the Game

Howard Fine - January 29, 2024

Biotechnology

Amgen Creates New Therapy Line

Howard Fine - December 4, 2023

Biotechnology

Cannabis-Centric DNA Test Lands U.S. Patent

Howard Fine - June 19, 2023

Biotechnology

A2 Biotherapeutics Starts ‘Tmod’ Drug Clinical Trials

Howard Fine - June 19, 2023

Biotechnology

Could FTC Amgen Lawsuit Have Ripple Effect?

SHERRY KARABIN - June 5, 2023

Biotechnology

Two Labs Debut in West San Fernando Valley

Howard Fine - May 22, 2023

Biotechnology

Acelyrin, Now Public, Focuses on Drug Pipeline

Howard Fine - May 22, 2023

Biotechnology

FTC Moves to Quash Amgen Deal

Howard Fine - May 22, 2023

Biotechnology

Acelyrin Raises $540M IPO; Shares Close Up 30% on First Day of Trading

Howard Fine - May 5, 2023

Biotechnology

Fewer, But Larger, Local Bioscience Funding Deals

Howard Fine - March 27, 2023

Biotechnology

Arcutis Drug Is with FDA for Approval

Howard Fine - March 27, 2023

Biotechnology

Amgen to Lay Off 450, Citing Inflation, Prices

Howard Fine - March 27, 2023

Biotechnology

Local Leaders

Howard Fine - March 13, 2023

Biotechnology

A Woman of Substance

Howard Fine - March 13, 2023

Biotechnology

PBS Biotech Raises $22 Million

Antonio Pequeño IV - January 13, 2023

Biotechnology

Dantari Raises $47M in Round

ANTONIO PEQUEÑO IV - January 2, 2023

Biotechnology

Amgen to Acquire Horizon Therapeutics in $27.8 Billion Deal

Antonio Pequeño IV - December 12, 2022

Biotechnology

Med Firm Gets Grant

Antonio Pequeño IV - December 5, 2022

Biotechnology

Atara Biotherapeutics Reports Inducement Grant

Antonio Pequeño IV - December 2, 2022

Biotechnology

Amgen Research and Development Facility Opens in Bay Area

ANTONIO PEQUEÑO IV - October 6, 2022

Biotechnology

Acelyrin Raises $300M to Further Growth

Gina Hall - September 26, 2022

Biotechnology

Arcutis Buys British Drug Developer

Mark Madler - September 26, 2022

Join Our Membership

Biotechnology

TriMed Reaches End Stage In Deal with Henry Schein

Brent Reinke and the 101 Biotech Corridor

Skin in the Game

Amgen Creates New Therapy Line

Cannabis-Centric DNA Test Lands U.S. Patent

A2 Biotherapeutics Starts ‘Tmod’ Drug Clinical Trials

Could FTC Amgen Lawsuit Have Ripple Effect?

Two Labs Debut in West San Fernando Valley

Acelyrin, Now Public, Focuses on Drug Pipeline

FTC Moves to Quash Amgen Deal

Acelyrin Raises $540M IPO; Shares Close Up 30% on First Day of Trading

Fewer, But Larger, Local Bioscience Funding Deals

Arcutis Drug Is with FDA for Approval

Amgen to Lay Off 450, Citing Inflation, Prices

Local Leaders

A Woman of Substance

PBS Biotech Raises $22 Million

Dantari Raises $47M in Round

Amgen to Acquire Horizon Therapeutics in $27.8 Billion Deal

Med Firm Gets Grant

Atara Biotherapeutics Reports Inducement Grant

Amgen Research and Development Facility Opens in Bay Area

Acelyrin Raises $300M to Further Growth

Arcutis Buys British Drug Developer

ADVERTISE WITH US

ABOUT US

Membership Center

OTHER JOURNALS